Prevention and treatment of cancers by tumor antigen-expressing
Immunity
Immunotherapy
Microbiome
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
22
5
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
epublish
Résumé
In a recent paper in
Identifiants
pubmed: 37205984
doi: 10.1080/2162402X.2023.2212547
pii: 2212547
pmc: PMC10190176
doi:
Substances chimiques
Antigens, Neoplasm
0
Types de publication
Editorial
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
2212547Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
OK is a cofounder of Samsara Therapeutics. LZ has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. The funders had no role in the writing of the manuscript, or in the decision to publish.
Références
AMB Express. 2022 Oct 3;12(1):128
pubmed: 36190582
Immunity. 2016 Oct 18;45(4):931-943
pubmed: 27717798
Science. 2023 Apr 14;380(6641):203-210
pubmed: 37053311
Nat Med. 2022 Apr;28(4):690-703
pubmed: 35440726
Cancer Discov. 2022 Oct 5;12(10):2280-2307
pubmed: 35929803
Front Microbiol. 2020 Apr 21;11:688
pubmed: 32373098
Cell. 2018 Feb 8;172(4):784-796.e18
pubmed: 29358051
Curr Opin Immunol. 2022 Apr;75:102171
pubmed: 35219942
Nat Med. 2023 Jan;29(1):59-74
pubmed: 36658422